71233-08-4

Basic information

• Product Name: N-benzoyl-N’-(2,4-dichlorophenyl)thiourea
• Synonyms: N-benzoyl-N’-(2,4-dichlorophenyl)thiourea
• CAS NO: 71233-08-4
• Molecular Weight: 325.218
• Mol File: 71233-08-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N-benzoyl-N’-(2,4-dichlorophenyl)thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzoyl-N’-(2,4-dichlorophenyl)thiourea(71233-08-4)
• EPA Substance Registry System: N-benzoyl-N’-(2,4-dichlorophenyl)thiourea(71233-08-4)

Safety Data

• Hazardous Substances Data: 71233-08-4(Hazardous Substances Data)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 554-00-7 2,4-Dichloroaniline 
• 98-88-4 benzoyl chloride 
• 532-55-8 Benzoyl isothiocyanate 
• 65-85-0 benzoic acid 

Downstream Products

• 1485525-17-4 N-(4-ferrocenylphenyl-N’-(2,4-dichlorophenyl))-N”-benzoylguanidine 
• 1485525-32-3 N-(3-ferrocenylphenyl-N’-(2,4-dichlorophenyl))-N”-benzoylguanidine 
• 108107-53-5 C₂₅H₁₆Cl₂N₄O₄S 
• 108107-52-4 C₂₄H₁₃Cl₃N₄O₃S 
• 108107-51-3 C₂₅H₁₆Cl₂N₄O₃S 
• 108107-50-2 C₂₄H₁₄Cl₂N₄O₃S 
• 6326-14-3 2,4-dichlorophenylthiourea 

Relevant articles and documents

SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS

The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

Solution-phase microwave assisted parallel synthesis of N,N′-disubstituted thioureas derived from benzoic acid: Biological evaluation and molecular docking studies

An efficient and facile microwave-assisted solution phase parallel synthesis for a 26-member library of N,N′-disubstituted thiourea analogs were accomplished successfully. The reaction time for synthesis of analogs was drastically reduced from a reported 8-12 h to only 10 min. Compounds were more than 95% pure, as characterized by modern analytical techniques, i.e. 1H & 13C NMR and FT-IR. The solid phase structural analysis has also been performed by single crystal XRD analysis. Synthesized compounds were preliminary screened for their in vitro urease inhibition and antifungal activity. Most of the compounds were found to be potent inhibitors of urease. However, the most significant activity was found for 11 with IC 50 of 1.67 μM. The docking scores correlate with the IC 50 values of inhibitors.